Loop Bio is developing LOOP-1015, a novel CNS therapy for obsessive-compulsive disorder (OCD) and Tourette Syndrome (TS). Our approach targets the brain circuitry implicated in both disorders, with a focus on safety and tolerability. Founded by a physician with lived experience of OCD and a world authority on OCD and TS pathophysiology.
No new OCD drugs have been approved in over 20 years. The only FDA-approved options for Tourette Syndrome are antipsychotics with severe side effects. Patients deserve better.
LOOP-1015 is a novel small molecule designed to address the brain circuitry implicated in OCD and Tourette Syndrome. The program builds on extensive prior clinical experience with related compounds, supporting a strong safety and tolerability profile.
| OCD | Tourette Syndrome | |
|---|---|---|
| Population | Adjunctive refractory / monotherapy | 2nd-line moderate-severe / all TS |
| Endpoint | Y-BOCS II superior to placebo | YGTSS TTS superior to placebo |
| Safety edge | No sexual dysfunction or emotional blunting | No movement disorders, sedation, or weight gain |
| Dosage | Chronic, oral, once daily | |
In collaboration with the Pittenger Lab at Yale, the program has generated convergent preclinical evidence across multiple translational readouts — behavioral, molecular, and circuit-level — supporting the proposed mechanism in OCD and Tourette Syndrome.
Loop Bio holds composition-of-matter and method-of-treatment claims providing broad exclusivity through 2047 and beyond, across OCD, tic disorders, and related indications.
